Compare SHBI & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SHBI | ZVRA |
|---|---|---|
| Founded | 1876 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 619.7M | 502.7M |
| IPO Year | N/A | 2015 |
| Metric | SHBI | ZVRA |
|---|---|---|
| Price | $18.47 | $8.87 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $18.75 | ★ $21.71 |
| AVG Volume (30 Days) | 151.9K | ★ 1.0M |
| Earning Date | 01-28-2026 | 03-10-2026 |
| Dividend Yield | ★ 2.61% | N/A |
| EPS Growth | ★ 38.21 | N/A |
| EPS | ★ 1.71 | 0.54 |
| Revenue | ★ $212,493,000.00 | $84,388,000.00 |
| Revenue This Year | N/A | $333.64 |
| Revenue Next Year | $7.96 | $43.58 |
| P/E Ratio | ★ $10.77 | $16.06 |
| Revenue Growth | 10.07 | ★ 244.60 |
| 52 Week Low | $11.47 | $6.19 |
| 52 Week High | $19.39 | $13.16 |
| Indicator | SHBI | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 55.01 | 51.93 |
| Support Level | $18.29 | $8.75 |
| Resistance Level | $18.62 | $9.60 |
| Average True Range (ATR) | 0.47 | 0.46 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 45.98 | 53.29 |
Shore Bancshares Inc is a financial holding company. It offers personalized banking, insurance, and investment services to families and businesses in the Mid-Atlantic region. It operates in one business segment- banking. The company's primary source of revenue is derived from interest earned on commercial, residential mortgage and other loans, and fees charged in connection with lending and other banking services located in Maryland, Delaware and Virginia.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.